RZRonglan Zhao

Ronglan Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ronglan Zhao has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaoxiang Peng

    School of Medical Laboratory, Shandong Second Medical University, Weifang, China

    11 shared publications
  • Xiaoxiang Peng

    School of Medical Laboratory, Shandong Second Medical University

    8 shared publications
  • Wei Song

    School of Medical Laboratory, Shandong Second Medical University, Shandong, China

    6 shared publications
  • Qingqing Yu

    School of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, China

    5 shared publications
  • Xin Wang

    School of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, China

    5 shared publications
  • Xue Bai

    School of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, China; Laboratory Department, WeiFang Mental Health Center, Weifang, 261072, Shandong, China

    4 shared publications

Latest Publications

  • Reverse Regulation of Th1 and Treg Immune Responses by P2X7 Receptor: A Possible Cause of the Progression of Experimental Autoimmune Uveitis

    by Yahui Cao, Xiaoxiang Peng, Shuping Luo, Yanan Du, Ronglan Zhao

    To study the regulatory effects and mechanisms of P2X7 receptors(P2X7R) on CD4+ regulatory T cells (Tregs) and pathogenic CD4+ T effector cells (Th1 cells). In this research, an experimental autoimmune uveitis (EAU) mouse model was established to investigate the impact of P2X7R on Th1 and Treg immune responses. During the initial stage of EAU, appropriate activation of P2X7R leads to an enhanced Th1 immune response, including an increased proportion of CD4+ IFN-γ+ Th1 cells, increased production of cytokines tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ), and upregulation of transcription factor T-bet expression. Conversely, activation of P2X7R resulted in inhibition of Treg immune response, including a reduced proportion of CD4+Foxp3+Tregs, a decreased in cytokines transforming growth factor-beta (TGF-β) and interleukin-10 (IL-10), and a downregulation of the transcription factor Foxp3 expression. Extracellular signal-regulated kinase 1/2 (ERK1/2) signal and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) may be related to these effects. Interestingly, we observed that both Th1 and Tregs immune responses were reduced in P2rx-/- mice compared with P2rx7+/+ mice. Our findings indicate that the promoting role of P2X7R in the early pathogenesis of EAU may be related to the contrary regulation of Th1 cells and Tregs, providing a new theoretical basis for the development of P2X7R targeted therapy.


  • The P2X7 receptor in leukemia: pathological mechanisms and therapeutic potential

    by Yanwen Xue, Xiaoxiang Peng, Meng Yan, Yanan Du, Yahui Cao, Ronglan Zhao

    The P2X7 receptor is a trimeric ion channel purinergic receptor. It plays a crucial part in the pathophysiology of cancers and a variety of inflammatory diseases and is widely expressed in different cell types. Leukemia represents a type of malignant clonal disorder that impacts the hematopoietic stem cells. Chemotherapy is one of the main treatment methods for leukemia, but there are also many side effects. In recent years, targeted therapy is a new treatment method. Research has shown that the progression and occurrence of leukemia is significantly related to the P2X7 receptor. The P2X7 receptor is also involved in the migration and invasion of leukemia cells. Furthermore, the polymorphism of the P2X7 receptor gene also takes on a significant function in the occurrence, development and clinical course of leukemia patients. The P2X7 receptor inhibitors have been found to work better in combination with existing therapeutics. Therefore, the P2X7 receptor may serve as a potential therapeutic target.


  • The Purinergic Ligand‐Gated Ion Channel 7 Receptor Promotes the Proliferation, Invasion, and Migration of Breast Cancer Cells

    by Xin Wang, Xiaoxiang Peng, Yahui Cao, Xiaodi Zhu, Yanan Du, Qingqing Yu, Ronglan Zhao

    Purinergic ligand‐gated ion channel 7 receptor (P2X7R) has essential functions in tumor proliferation, apoptosis, metastasis, and invasion, and the purpose of this study was to explore the effects of P2X7R on the biological behaviors of MCF‐7 and MDA‐MB‐231 cells. A bioinformatics analysis of P2X7R expression in breast cancer was performed and its relationships with overall survival and immune cell infiltration were determined. P2X7R ion channel function was detected via a Fluo‐4‐AM assay. Proliferation, migration and invasion were investigated using CCK‐8, scratch wound healing, and Transwell assays, respectively. The levels of P2X7R, JNK, p‐JNK, Akt, p‐Akt, E‐cadherin, N‐cadherin, vimentin and GAPDH were detected by western blotting. The role of P2X7R on the biological behaviors of MCF‐7 cells was detected in vivo. Bioinformatics analysis revealed an obvious increase in the expression of P2X7R in breast cancer and differences were observed among the different subtypes. High expression of P2X7R was negatively correlated with overall survival and affected immune cell infiltration. The experimental results revealed that both types of cells express functional P2X7R. ATP and BzATP can promote proliferation, invasion, and metastasis after P2X7R activation; upregulate p‐Akt, p‐JNK, N‐cadherin and vimentin; and downregulate E‐cadherin compared with the control group, and the addition of the antagonist A438079 or oxATP or the knockdown of P2X7R could weaken these effects. The activation of P2X7R in breast cancer cells can promote their biological behaviors, indicating that P2X7R is a latent therapeutic target in breast cancer.


  • Role of the P2X7 receptor in breast cancer progression

    by Yanan Du, Yahui Cao, Wei Song, Xin Wang, Qingqing Yu, Xiaoxiang Peng, Ronglan Zhao

    Breast cancer is a common malignant tumor, whose incidence is increasing year by year, and it has become the malignant tumor with the highest incidence rate in women. Purine ligand-gated ion channel 7 receptor (P2X7R) is a cation channel receptor with Adenosine triphosphate ( ATP) as a ligand, which is widely distributed in cells and tissues, and is closely related to tumorigenesis and progression. P2X7R plays an important role in cancer by interacting with ATP. Studies have shown that P2X7R is up-regulated in breast cancer and can promote tumor invasion and metastasis by activating the protein kinase B (AKT) signaling pathway, promoting epithelial-mesenchymal transition (EMT), controlling the generation of extracellular vesicle (EV), and regulating the expression of the inflammatory protein cyclooxygenase 2 (COX-2). Furthermore, P2X7R was proven to play an essential role in the proliferation and apoptosis of breast cancer cells. Recently, inhibitors targeting P2X7R have been found to inhibit the progression of breast cancer. Natural P2X7R antagonists, such as rhodopsin, and the isoquinoline alkaloid berberine, have also been shown to be effective in inhibiting breast cancer progression. In this article, we review the research progress of P2X7R and breast cancer intending to provide new targets and directions for breast cancer treatment.


  • The role of the purinergic ligand-gated ion channel 7 receptor in common digestive system cancers

    by Xin Wang, Qingqing Yu, Xue Bai, Xinyu Li, Yanli Sun, Xiaoxiang Peng, Ronglan Zhao

    The incidence of digestive malignancies has increased in recent years, including colorectal cancer (CRC), hepatocellular carcinoma (HCC) and pancreatic cancer. Advanced stages of these cancers are prone to metastasis, which seriously reduce the standard of living of patients and lead to decline in the survival rate of patients. So far there are no good specific drugs to stop this phenomenon. It is very important and urgent to find new biomarkers and therapeutic targets. Purinergic ligand-gated ion channel 7 receptor (P2X7R) is ATP-gated and nonselective ion channel receptor involved in many inflammatory processes and cancer progression. P2X7R is present in many cancer cells and promotes or inhibits cancer development through signal transduction. Studies have presented that P2X7R plays a role in the proliferation and migration of digestive system cancers, such as CRC, HCC and pancreatic cancer. Therefore, P2X7R may serve as a biomarker or therapeutic target for digestive system cancers. This paper describes the structure and function of P2X7R, and mainly reviews the research progress on the role of P2X7R in CRC, HCC and pancreatic cancer.


  • Purinergic P2X7R as a potential target for pancreatic cancer

    by Qingqing Yu, Xin Wang, Xinyu Li, Xue Bai, Ronglan Zhao, Xiaoxiang Peng

    Pancreatic cancer is one of the deadliest types of cancer, with a death rate nearly equal to the incidence. The P2X7 receptor (P2X7R) is a kind of extracellular adenosine triphosphate (ATP)-gated ion channel with special permeability, which exists in most tissues of human body and mediates inflammation-related signaling pathways and immune signal transduction after activation. P2X7R is also present on the surface of several tumor cells and is involved in tumor growth and progression. P2X7R expression in pancreatic cancer has also been identified in recent studies. Activation of P2X7R in pancreatic cancer can support the proliferation of pancreatic stellate cells, participate in protein interactions, and mediate ERK1/2, IL-6/STAT3, hCAP-18/LL-37, PI3K/AKT signaling pathways to promote pancreatic cancer progression. Inhibitors targeting P2X7R can inhibit the development of pancreatic cancer and are expected to be used in clinical therapy. Therefore, P2X7R is promising as a potential therapeutic target for pancreatic cancer. This article reviews the progress of research on P2X7R in pancreatic cancer.


  • P2X7 receptor promotes migration and invasion of non-small cell lung cancer A549 cells through the PI3K/Akt pathways

    by Xue Bai, Qianqian Li, Xiaoxiang Peng, Xinyu Li, Cuicui Qiao, Yiqing Tang, Ronglan Zhao

    It has been demonstrated that the ATP-gated ion channel P2X7 receptor is involved in tumor progression and plays an important role in regulating tumor cell growth, invasion, migration and angiogenesis. However, P2X7 receptors have been relatively poorly studied in non-small cell lung cancer (NSCLC) cells. Therefore, the aim of this study was to investigate the effects of P2X7 receptor on A549 cells (NSCLC cell line) migration and invasion and to reveal the molecular mechanisms mediated by it. We detected the expression and function of P2X7 receptor in A549 cells. The effects and mechanisms of P2X7 receptor on A549 cells migration, invasion, and epithelial-mesenchymal transition were detected in vitro and in vivo. The results showed P2X7 receptor expressed by A549 cells had ion channel and macropore formation function. In addition, activation of P2X7 receptor by adenosine triphosphate (ATP) or 2′(3′)-O-(4-Benzoylbenzoyl)-adenosine-5'-triphosphate (BzATP) promoted Epithelial-mesenchymal transition (EMT), migration and invasion of A549 cells, which was attenuated by treatment of cells with P2X7 receptor antagonist A438079 and Oxidized ATP. Furthermore, activation of P2X7 receptor increased phosphorylated protein kinase B (p-Akt) levels, and the phosphatidylinositol-tris–phosphate kinase 3 (PI3K)/protein kinase B (Akt) inhibitor LY294002 blocked migration and invasion of A549 cells induced by ATP or BzATP. At the same time, in vivo results showed that P2X7 receptor could also promote EMT and PI3K/Akt expression in transplanted tumors. Our study indicated that P2X7 receptor promotes A549 cells migration and invasion through the PI3K/Akt signaling pathway, suggesting that P2X7 receptor may be a potential therapeutic target for NSCLC.


  • Research progress on the P2X7 receptor in liver injury and hepatocellular carcinoma

    by Xinyu Li, Xue Bai, Yiqing Tang, Cuicui Qiao, Ronglan Zhao, Xiaoxiang Peng

    Purinergic ligand‐gated ion channel 7 receptor (P2X7 receptor) is an adenosine triphosphate (ATP)‐gated ion channel that is widely distributed on the surfaces of immune cells and tissues such as those in the liver, kidney, lung, intestine, and nervous system. Hepatocellular carcinoma (HCC) is one of the most common malignancies with increasing incidence and mortality. Although many treatments for liver cancer have been studied, the prognosis for liver cancer is still very poor. Therefore, new liver cancer treatments are urgently needed. P2X7 receptor activation can secrete proinflammatory factors through the P2X7 receptor‐NLRP3 signaling pathway, thereby affecting the progression of liver injury. The P2X7 receptor may be a target for growth inhibition of HCC cells and may affect the invasion and migration of HCC cells through the PI3K/AKT and AMPK signaling pathways. In recent years, P2X7 receptor antagonists or inhibitors have attracted widespread attention as therapeutic targets for hepatocellular carcinoma and liver injury. Therefore, this review covers the basic concepts of the P2X7 receptor and role of the P2X7 receptor in liver cancer and liver injury, providing new potential therapeutic targets for hepatocellular carcinoma and liver injury.